| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart Failure | 39 | 2019 | 6638 | 4.80 | Why? |
| Emergency Medicine | 12 | 2020 | 936 | 3.91 | Why? |
| Emergency Service, Hospital | 49 | 2021 | 14232 | 3.06 | Why? |
| Spain | 51 | 2021 | 15545 | 2.08 | Why? |
| Periodicals as Topic | 8 | 2019 | 1492 | 1.96 | Why? |
| Journal Impact Factor | 4 | 2019 | 134 | 1.89 | Why? |
| Patient Readmission | 6 | 2019 | 1543 | 1.61 | Why? |
| Efficiency | 3 | 2018 | 420 | 1.59 | Why? |
| Acute Disease | 29 | 2021 | 6029 | 1.58 | Why? |
| Cocaine-Related Disorders | 2 | 2019 | 51 | 1.47 | Why? |
| Cocaine | 2 | 2019 | 73 | 1.47 | Why? |
| Relaxin | 2 | 2018 | 25 | 1.42 | Why? |
| Emergency Medical Services | 7 | 2020 | 3557 | 1.19 | Why? |
| Registries | 19 | 2019 | 12327 | 1.14 | Why? |
| Diet, Mediterranean | 2 | 2018 | 351 | 1.01 | Why? |
| Crack Cocaine | 2 | 2019 | 8 | 1.01 | Why? |
| Bronchodilator Agents | 2 | 2019 | 444 | 1.00 | Why? |
| Pulmonary Embolism | 7 | 2021 | 4775 | 0.99 | Why? |
| Editorial Policies | 2 | 2019 | 408 | 0.99 | Why? |
| Publishing | 4 | 2019 | 990 | 0.99 | Why? |
| Glycopeptides | 4 | 2017 | 199 | 0.96 | Why? |
| Stroke Volume | 5 | 2019 | 2153 | 0.95 | Why? |
| Pancreatitis | 2 | 2021 | 688 | 0.94 | Why? |
| Pneumothorax | 2 | 2020 | 758 | 0.91 | Why? |
| Length of Stay | 9 | 2020 | 11042 | 0.91 | Why? |
| Biomedical Research | 6 | 2020 | 5270 | 0.88 | Why? |
| Beds | 1 | 2021 | 79 | 0.87 | Why? |
| Guillain-Barre Syndrome | 4 | 2021 | 1495 | 0.85 | Why? |
| Hospital Mortality | 21 | 2021 | 22087 | 0.84 | Why? |
| Patient Discharge | 5 | 2019 | 5696 | 0.82 | Why? |
| Myocardial Infarction | 15 | 2019 | 3361 | 0.82 | Why? |
| Troponin T | 6 | 2018 | 771 | 0.71 | Why? |
| Sodium Oxybate | 1 | 2017 | 14 | 0.71 | Why? |
| Hospital Administrators | 1 | 2018 | 50 | 0.70 | Why? |
| 4-Butyrolactone | 1 | 2017 | 18 | 0.70 | Why? |
| Bibliometrics | 4 | 2019 | 731 | 0.67 | Why? |
| Hospitals, Public | 3 | 2020 | 774 | 0.67 | Why? |
| Morphine | 1 | 2017 | 71 | 0.66 | Why? |
| Galectin 3 | 1 | 2017 | 76 | 0.64 | Why? |
| Emergency Medical Technicians | 1 | 2017 | 104 | 0.60 | Why? |
| Survival Rate | 14 | 2019 | 9206 | 0.59 | Why? |
| Syncope | 4 | 2019 | 238 | 0.59 | Why? |
| Gastrointestinal Hemorrhage | 2 | 2022 | 669 | 0.59 | Why? |
| Antiretroviral Therapy, Highly Active | 4 | 2017 | 952 | 0.59 | Why? |
| Acute Coronary Syndrome | 5 | 2021 | 2107 | 0.57 | Why? |
| Troponin I | 6 | 2018 | 1298 | 0.57 | Why? |
| Pericarditis | 1 | 2020 | 417 | 0.56 | Why? |
| Aged, 80 and over | 40 | 2021 | 88759 | 0.55 | Why? |
| HIV-Associated Lipodystrophy Syndrome | 3 | 2011 | 15 | 0.55 | Why? |
| Noninvasive Ventilation | 2 | 2018 | 2329 | 0.55 | Why? |
| Hemostasis | 1 | 2021 | 811 | 0.55 | Why? |
| Emergency Nursing | 1 | 2017 | 146 | 0.54 | Why? |
| Computed Tomography Angiography | 3 | 2020 | 2153 | 0.53 | Why? |
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 3832 | 0.53 | Why? |
| Risk Assessment | 11 | 2021 | 25439 | 0.53 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.51 | Why? |
| Mitochondria | 3 | 2011 | 857 | 0.51 | Why? |
| Hypnotics and Sedatives | 1 | 2019 | 624 | 0.50 | Why? |
| Accidental Falls | 1 | 2018 | 448 | 0.50 | Why? |
| Clinical Protocols | 3 | 2021 | 2734 | 0.50 | Why? |
| Health Care Surveys | 2 | 2020 | 2942 | 0.50 | Why? |
| Substance-Related Disorders | 2 | 2018 | 2038 | 0.49 | Why? |
| Natriuretic Peptide, Brain | 2 | 2017 | 1215 | 0.49 | Why? |
| Geriatric Assessment | 2 | 2018 | 1372 | 0.48 | Why? |
| Propensity Score | 3 | 2018 | 2690 | 0.48 | Why? |
| Intensive Care Units | 7 | 2021 | 29594 | 0.47 | Why? |
| Hospital Units | 1 | 2019 | 1017 | 0.47 | Why? |
| Peptide Fragments | 3 | 2017 | 2075 | 0.47 | Why? |
| Risk Factors | 29 | 2022 | 71621 | 0.46 | Why? |
| Prognosis | 22 | 2021 | 32490 | 0.46 | Why? |
| Patients' Rooms | 1 | 2016 | 675 | 0.46 | Why? |
| Male | 73 | 2021 | 367725 | 0.46 | Why? |
| Humans | 112 | 2022 | 930598 | 0.46 | Why? |
| Transportation of Patients | 1 | 2017 | 494 | 0.45 | Why? |
| Female | 74 | 2021 | 380317 | 0.45 | Why? |
| Job Satisfaction | 1 | 2017 | 647 | 0.44 | Why? |
| Biomarkers | 17 | 2019 | 23361 | 0.44 | Why? |
| Aged | 56 | 2021 | 215776 | 0.44 | Why? |
| Patient Compliance | 2 | 2017 | 1468 | 0.42 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.42 | Why? |
| Drug Overdose | 1 | 2017 | 583 | 0.41 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.40 | Why? |
| Lactates | 1 | 2009 | 59 | 0.40 | Why? |
| Time Factors | 18 | 2020 | 31397 | 0.40 | Why? |
| Prospective Studies | 32 | 2020 | 43301 | 0.39 | Why? |
| Europe | 14 | 2019 | 12702 | 0.39 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2011 | 309 | 0.38 | Why? |
| Follow-Up Studies | 17 | 2019 | 17020 | 0.38 | Why? |
| Attitude of Health Personnel | 2 | 2018 | 4741 | 0.38 | Why? |
| Hallucinogens | 1 | 2008 | 12 | 0.37 | Why? |
| Incidence | 14 | 2022 | 25622 | 0.37 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.37 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.37 | Why? |
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2008 | 21 | 0.36 | Why? |
| Glomerular Filtration Rate | 4 | 2021 | 1262 | 0.36 | Why? |
| Odds Ratio | 5 | 2020 | 5861 | 0.36 | Why? |
| Cause of Death | 7 | 2019 | 4823 | 0.36 | Why? |
| Language | 1 | 2013 | 655 | 0.35 | Why? |
| Medical Staff, Hospital | 1 | 2018 | 1258 | 0.34 | Why? |
| Physicians | 2 | 2017 | 4214 | 0.34 | Why? |
| Hyperkalemia | 2 | 2019 | 140 | 0.33 | Why? |
| Kidney | 2 | 2018 | 3648 | 0.32 | Why? |
| Algorithms | 9 | 2019 | 7346 | 0.32 | Why? |
| Diuretics | 2 | 2019 | 326 | 0.32 | Why? |
| Troponin | 5 | 2019 | 1058 | 0.31 | Why? |
| Health Education | 1 | 2018 | 1539 | 0.31 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.30 | Why? |
| Dyspnea | 1 | 2019 | 3847 | 0.30 | Why? |
| Retrospective Studies | 20 | 2022 | 105322 | 0.30 | Why? |
| Adipose Tissue | 1 | 2011 | 612 | 0.29 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.29 | Why? |
| Cardiology | 2 | 2018 | 2873 | 0.29 | Why? |
| Societies, Medical | 2 | 2018 | 6907 | 0.29 | Why? |
| Wounds and Injuries | 1 | 2018 | 1708 | 0.28 | Why? |
| Logistic Models | 6 | 2020 | 9089 | 0.28 | Why? |
| Mitochondria, Muscle | 1 | 2003 | 8 | 0.28 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.27 | Why? |
| Electron Transport Complex IV | 1 | 2003 | 21 | 0.27 | Why? |
| Frail Elderly | 3 | 2019 | 1427 | 0.27 | Why? |
| Carbon Monoxide Poisoning | 1 | 2003 | 24 | 0.26 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.26 | Why? |
| Predictive Value of Tests | 11 | 2020 | 9537 | 0.26 | Why? |
| Electrocardiography | 6 | 2019 | 3957 | 0.25 | Why? |
| DNA, Mitochondrial | 2 | 2017 | 163 | 0.24 | Why? |
| Non-ST Elevated Myocardial Infarction | 2 | 2018 | 490 | 0.24 | Why? |
| Circadian Rhythm | 2 | 2019 | 607 | 0.24 | Why? |
| Asthma | 2 | 2020 | 4383 | 0.24 | Why? |
| Early Diagnosis | 7 | 2018 | 2443 | 0.23 | Why? |
| Adrenal Cortex Hormones | 1 | 2019 | 6537 | 0.23 | Why? |
| Proportional Hazards Models | 3 | 2019 | 6543 | 0.23 | Why? |
| Decision Support Techniques | 3 | 2018 | 903 | 0.22 | Why? |
| Apoptosis | 2 | 2017 | 2335 | 0.22 | Why? |
| Emergencies | 3 | 2018 | 4095 | 0.22 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.22 | Why? |
| Case-Control Studies | 6 | 2021 | 17671 | 0.21 | Why? |
| United States Food and Drug Administration | 2 | 2018 | 1276 | 0.20 | Why? |
| Triage | 4 | 2020 | 7151 | 0.19 | Why? |
| Middle Aged | 39 | 2021 | 270681 | 0.19 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.19 | Why? |
| Journalism, Medical | 1 | 2019 | 50 | 0.18 | Why? |
| Respiration, Artificial | 3 | 2020 | 22116 | 0.18 | Why? |
| Absenteeism | 1 | 2020 | 287 | 0.18 | Why? |
| Muscle, Skeletal | 1 | 2005 | 915 | 0.18 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.18 | Why? |
| Research Personnel | 2 | 2020 | 1037 | 0.18 | Why? |
| Meningoencephalitis | 1 | 2021 | 208 | 0.18 | Why? |
| Akathisia, Drug-Induced | 1 | 2017 | 6 | 0.18 | Why? |
| Precipitating Factors | 1 | 2017 | 31 | 0.18 | Why? |
| Advanced Cardiac Life Support | 1 | 2017 | 75 | 0.18 | Why? |
| Endothelin-1 | 1 | 2017 | 69 | 0.18 | Why? |
| Confidence Intervals | 1 | 2020 | 744 | 0.17 | Why? |
| Atrial Natriuretic Factor | 1 | 2017 | 75 | 0.17 | Why? |
| Zidovudine | 1 | 2017 | 63 | 0.17 | Why? |
| MEDLINE | 1 | 2017 | 76 | 0.17 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.17 | Why? |
| Stroke | 1 | 2021 | 8839 | 0.17 | Why? |
| Kidney Diseases | 2 | 2019 | 1434 | 0.17 | Why? |
| Analysis of Variance | 1 | 2020 | 950 | 0.17 | Why? |
| Personnel Administration, Hospital | 1 | 2017 | 70 | 0.16 | Why? |
| Chest Pain | 2 | 2018 | 578 | 0.16 | Why? |
| Narcotics | 1 | 2017 | 67 | 0.16 | Why? |
| Health Resources | 3 | 2020 | 2592 | 0.16 | Why? |
| Galectins | 1 | 2017 | 109 | 0.16 | Why? |
| Risk Adjustment | 1 | 2020 | 730 | 0.16 | Why? |
| Injections, Intravenous | 1 | 2017 | 381 | 0.15 | Why? |
| Sex Distribution | 2 | 2020 | 2083 | 0.15 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.15 | Why? |
| HIV Infections | 4 | 2017 | 11620 | 0.15 | Why? |
| Practice Patterns, Nurses' | 1 | 2018 | 140 | 0.15 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.15 | Why? |
| Early Medical Intervention | 1 | 2019 | 487 | 0.15 | Why? |
| Maternal-Fetal Exchange | 1 | 2017 | 209 | 0.15 | Why? |
| Consciousness | 1 | 2017 | 140 | 0.15 | Why? |
| Mineralocorticoid Receptor Antagonists | 1 | 2017 | 203 | 0.15 | Why? |
| HIV-1 | 1 | 2011 | 3365 | 0.15 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.15 | Why? |
| Treatment Outcome | 7 | 2018 | 51732 | 0.15 | Why? |
| Internationality | 2 | 2018 | 3297 | 0.15 | Why? |
| Motor Activity | 1 | 2017 | 217 | 0.15 | Why? |
| Hypokalemia | 1 | 2017 | 195 | 0.15 | Why? |
| Adrenomedullin | 1 | 2017 | 217 | 0.14 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.14 | Why? |
| Potassium | 1 | 2017 | 325 | 0.14 | Why? |
| Nutrition Assessment | 1 | 2019 | 527 | 0.14 | Why? |
| Pulmonary Edema | 1 | 2019 | 430 | 0.14 | Why? |
| Hospital Design and Construction | 1 | 2018 | 287 | 0.14 | Why? |
| Workplace Violence | 1 | 2017 | 100 | 0.14 | Why? |
| Family | 1 | 2009 | 2909 | 0.14 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.14 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.14 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.14 | Why? |
| Work-Life Balance | 1 | 2017 | 212 | 0.14 | Why? |
| Ambulances | 1 | 2017 | 287 | 0.14 | Why? |
| Intubation, Intratracheal | 3 | 2020 | 3962 | 0.14 | Why? |
| Coronary Disease | 1 | 2020 | 645 | 0.14 | Why? |
| Chronic Disease | 1 | 2009 | 5139 | 0.14 | Why? |
| Echocardiography | 2 | 2018 | 3661 | 0.14 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.13 | Why? |
| Adrenergic beta-Antagonists | 1 | 2017 | 465 | 0.13 | Why? |
| Protein Precursors | 1 | 2017 | 425 | 0.13 | Why? |
| Patient Care Planning | 1 | 2019 | 582 | 0.13 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.13 | Why? |
| Age Distribution | 2 | 2020 | 3567 | 0.13 | Why? |
| Dyslipidemias | 1 | 2020 | 791 | 0.13 | Why? |
| Adult | 22 | 2021 | 244371 | 0.13 | Why? |
| Nebulizers and Vaporizers | 1 | 2017 | 497 | 0.13 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.13 | Why? |
| Research Design | 3 | 2019 | 5830 | 0.13 | Why? |
| Authorship | 1 | 2016 | 240 | 0.13 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.12 | Why? |
| Mortality | 3 | 2019 | 7132 | 0.12 | Why? |
| Longitudinal Studies | 3 | 2017 | 9893 | 0.12 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.12 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| Patient Transfer | 1 | 2019 | 898 | 0.11 | Why? |
| Crowding | 1 | 2018 | 731 | 0.11 | Why? |
| Quality Indicators, Health Care | 1 | 2017 | 580 | 0.11 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.11 | Why? |
| Patient Admission | 2 | 2018 | 5250 | 0.11 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.11 | Why? |
| Hospitals | 3 | 2021 | 11793 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
| Up-Regulation | 4 | 2018 | 2249 | 0.10 | Why? |
| Heart Ventricles | 1 | 2018 | 1139 | 0.10 | Why? |
| Malnutrition | 1 | 2019 | 932 | 0.10 | Why? |
| Cooperative Behavior | 1 | 2017 | 1216 | 0.10 | Why? |
| Personnel, Hospital | 2 | 2020 | 2273 | 0.10 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.10 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.10 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.10 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.09 | Why? |
| Aftercare | 1 | 2019 | 1637 | 0.09 | Why? |
| Mitochondrial Proteins | 1 | 2009 | 152 | 0.09 | Why? |
| Temperature | 1 | 2019 | 2305 | 0.09 | Why? |
| Resource Allocation | 1 | 2020 | 1771 | 0.09 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.09 | Why? |
| Heart Rate | 1 | 2018 | 1527 | 0.09 | Why? |
| Quality Improvement | 2 | 2019 | 2435 | 0.09 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.09 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.09 | Why? |
| Professional Role | 1 | 2017 | 1280 | 0.09 | Why? |
| Nutritional Status | 1 | 2018 | 1403 | 0.09 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.08 | Why? |
| Clinical Decision-Making | 2 | 2018 | 3755 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Sensitivity and Specificity | 5 | 2019 | 22971 | 0.08 | Why? |
| Dementia | 1 | 2020 | 1861 | 0.08 | Why? |
| Placenta | 1 | 2017 | 1531 | 0.08 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.08 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.08 | Why? |
| In Situ Nick-End Labeling | 1 | 2005 | 39 | 0.08 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 436 | 0.08 | Why? |
| Disabled Persons | 1 | 2017 | 1152 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Seasons | 1 | 2019 | 4071 | 0.08 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.07 | Why? |
| Poisoning | 1 | 2008 | 176 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.07 | Why? |
| Nevirapine | 1 | 2005 | 57 | 0.07 | Why? |
| Pyrimidinones | 1 | 2005 | 76 | 0.07 | Why? |
| Knowledge | 1 | 2009 | 452 | 0.07 | Why? |
| Reproducibility of Results | 5 | 2018 | 11304 | 0.07 | Why? |
| Nursing Staff, Hospital | 1 | 2018 | 1554 | 0.07 | Why? |
| France | 1 | 2020 | 12074 | 0.07 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.07 | Why? |
| Gene Expression Regulation, Viral | 1 | 2009 | 925 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.06 | Why? |
| Checklist | 2 | 2019 | 714 | 0.06 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.06 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.06 | Why? |
| Hypoxia | 1 | 2017 | 3626 | 0.06 | Why? |
| RNA | 1 | 2009 | 1278 | 0.06 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.06 | Why? |
| Schools | 1 | 2018 | 4187 | 0.06 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2018 | 3051 | 0.06 | Why? |
| New Zealand | 2 | 2019 | 2073 | 0.06 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2017 | 3892 | 0.05 | Why? |
| Gastroscopy | 1 | 2022 | 112 | 0.05 | Why? |
| United States | 5 | 2019 | 46150 | 0.05 | Why? |
| In Vitro Techniques | 1 | 2003 | 1027 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.05 | Why? |
| Matched-Pair Analysis | 1 | 2019 | 83 | 0.05 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.05 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 5277 | 0.05 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.05 | Why? |
| Angina, Unstable | 1 | 2019 | 110 | 0.05 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Atrioventricular Block | 1 | 2019 | 105 | 0.04 | Why? |
| Far East | 1 | 2018 | 125 | 0.04 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.04 | Why? |
| Contraindications | 1 | 2017 | 96 | 0.04 | Why? |
| Myocardial Revascularization | 1 | 2019 | 267 | 0.04 | Why? |
| Infant, Small for Gestational Age | 1 | 2017 | 151 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2018 | 15421 | 0.04 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.04 | Why? |
| Australia | 2 | 2019 | 6306 | 0.04 | Why? |
| Carrier Proteins | 1 | 2018 | 513 | 0.04 | Why? |
| Neoplasms | 2 | 2020 | 17251 | 0.04 | Why? |
| Respiration Disorders | 1 | 2020 | 526 | 0.03 | Why? |
| Lung | 2 | 2021 | 31049 | 0.03 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Fetal Blood | 1 | 2017 | 573 | 0.03 | Why? |
| Disability Evaluation | 1 | 2017 | 671 | 0.03 | Why? |
| Prenatal Exposure Delayed Effects | 1 | 2017 | 319 | 0.03 | Why? |
| Reference Standards | 1 | 2017 | 1163 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.03 | Why? |
| ROC Curve | 2 | 2017 | 6024 | 0.03 | Why? |
| Shock, Cardiogenic | 1 | 2019 | 700 | 0.03 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Creatinine | 1 | 2017 | 1443 | 0.03 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Ritonavir | 1 | 2005 | 4212 | 0.02 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.02 | Why? |
| Heart Arrest | 1 | 2019 | 1239 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.02 | Why? |
| Arrhythmias, Cardiac | 1 | 2019 | 2510 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Drug Tolerance | 1 | 2005 | 100 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.02 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.02 | Why? |
| Cholesterol, HDL | 1 | 2005 | 439 | 0.01 | Why? |
| Cholesterol, LDL | 1 | 2005 | 499 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.01 | Why? |
| Lipids | 1 | 2005 | 1079 | 0.01 | Why? |
| Safety | 1 | 2005 | 1583 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Lopinavir | 1 | 2005 | 4308 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |